• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Extension of the thrombolytic time window with minocycline in experimental stroke.米诺环素在实验性卒中中延长溶栓时间窗
Stroke. 2008 Dec;39(12):3372-7. doi: 10.1161/STROKEAHA.108.514026. Epub 2008 Oct 16.
2
Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats.基质金属蛋白酶在大鼠栓塞性局灶性缺血后溶栓相关出血转化中的作用。
Stroke. 2002 Mar;33(3):831-6. doi: 10.1161/hs0302.104542.
3
Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia.常压高氧可减少局灶性脑缺血大鼠模型中与组织型纤溶酶原激活剂延迟治疗相关的神经血管并发症。
Stroke. 2009 Jul;40(7):2526-31. doi: 10.1161/STROKEAHA.108.545483. Epub 2009 May 28.
4
Effects of minocycline plus tissue plasminogen activator combination therapy after focal embolic stroke in type 1 diabetic rats.1 型糖尿病大鼠局灶性栓塞性卒中后米诺环素联合组织型纤溶酶原激活剂联合治疗的效果。
Stroke. 2013 Mar;44(3):745-52. doi: 10.1161/STROKEAHA.111.000309. Epub 2013 Feb 19.
5
Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats.自由基自旋捕获减少大鼠栓塞性局灶性脑缺血后组织型纤溶酶原激活剂诱导的出血和脑损伤
J Cereb Blood Flow Metab. 2000 Mar;20(3):452-7. doi: 10.1097/00004647-200003000-00002.
6
Progesterone attenuates hemorrhagic transformation after delayed tPA treatment in an experimental model of stroke in rats: involvement of the VEGF-MMP pathway.孕激素可减轻大鼠实验性卒中模型中 tPA 延迟治疗后的出血性转化:涉及 VEGF-MMP 通路。
J Cereb Blood Flow Metab. 2014 Jan;34(1):72-80. doi: 10.1038/jcbfm.2013.163. Epub 2013 Sep 18.
7
Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke.基质金属蛋白酶-9 在静脉注射米诺环素治疗急性缺血性卒中的探索性试验中。
Stroke. 2011 Sep;42(9):2633-5. doi: 10.1161/STROKEAHA.111.618215. Epub 2011 Jul 7.
8
Postischemic (6-Hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia.在栓塞性局灶性脑缺血大鼠模型中,用重组人组织型纤溶酶原激活剂和蛋白酶体抑制剂PS-519进行缺血后(6小时)治疗可减少梗死面积。
Stroke. 2001 Dec 1;32(12):2926-31. doi: 10.1161/hs1201.100207.
9
Transient brain hypothermia reduces the reperfusion injury of delayed tissue plasminogen activator and extends its therapeutic time window in a focal embolic stroke model.短暂性脑低温可减轻延迟性组织型纤溶酶原激活剂再灌注损伤,并延长其在局灶性栓塞性卒中模型中的治疗时间窗。
Brain Res Bull. 2017 Sep;134:85-90. doi: 10.1016/j.brainresbull.2017.07.007. Epub 2017 Jul 11.
10
Combination therapy with normobaric oxygen (NBO) plus thrombolysis in experimental ischemic stroke.常压氧(NBO)联合溶栓治疗实验性缺血性中风。
BMC Neurosci. 2009 Jul 15;10:79. doi: 10.1186/1471-2202-10-79.

引用本文的文献

1
Matrix metalloproteinase‑9 in hemorrhagic transformation after acute ischemic stroke (Review).基质金属蛋白酶-9与急性缺血性卒中后的出血性转化(综述)
Mol Med Rep. 2025 Aug;32(2). doi: 10.3892/mmr.2025.13590. Epub 2025 Jun 6.
2
The role of neutrophils in tPA thrombolysis after stroke: a malicious troublemaker.中性粒细胞在中风后 tPA 溶栓中的作用:一个恶意的捣蛋鬼。
Front Immunol. 2024 Nov 13;15:1477669. doi: 10.3389/fimmu.2024.1477669. eCollection 2024.
3
Differences in Acute Expression of Matrix Metalloproteinases-9, 3, and 2 Related to the Duration of Brain Ischemia and Tissue Plasminogen Activator Treatment in Experimental Stroke.实验性脑卒中与脑缺血持续时间及组织型纤溶酶原激活剂治疗相关的基质金属蛋白酶-9、3、2 的急性表达差异。
Int J Mol Sci. 2024 Aug 30;25(17):9442. doi: 10.3390/ijms25179442.
4
The case for neuregulin-1 as a clinical treatment for stroke.将神经调节蛋白-1作为中风临床治疗手段的理由。
Front Cell Neurosci. 2024 Apr 4;18:1325630. doi: 10.3389/fncel.2024.1325630. eCollection 2024.
5
Evolving Clinical-Translational Investigations of Cerebroprotection in Ischemic Stroke.缺血性卒中脑保护的临床转化研究进展
J Clin Med. 2023 Oct 24;12(21):6715. doi: 10.3390/jcm12216715.
6
Minocycline attenuates hydrocephalus and inhibits iron accumulation, ependymal damage and epiplexus cell activation after intraventricular hemorrhage in aged rats.米诺环素可减轻脑积水,并抑制老年大鼠脑室出血后铁积累、室管膜损伤和室管膜下胶质细胞激活。
Exp Neurol. 2023 Nov;369:114523. doi: 10.1016/j.expneurol.2023.114523. Epub 2023 Aug 30.
7
The Role of Matrix Metalloproteinases in Hemorrhagic Transformation in the Treatment of Stroke with Tissue Plasminogen Activator.基质金属蛋白酶在组织型纤溶酶原激活剂治疗中风后出血转化中的作用
J Pers Med. 2023 Jul 23;13(7):1175. doi: 10.3390/jpm13071175.
8
Animal Models of Ischemic Stroke with Different Forms of Middle Cerebral Artery Occlusion.不同形式大脑中动脉闭塞性缺血性中风的动物模型
Brain Sci. 2023 Jun 29;13(7):1007. doi: 10.3390/brainsci13071007.
9
Matrix Metalloproteinases in Cardioembolic Stroke: From Background to Complications.心肌梗死后心脏破裂的危险因素分析
Int J Mol Sci. 2023 Feb 11;24(4):3628. doi: 10.3390/ijms24043628.
10
Gut microbiota in ischemic stroke: Where we stand and challenges ahead.缺血性卒中中的肠道微生物群:我们的现状与面临的挑战
Front Nutr. 2022 Dec 1;9:1008514. doi: 10.3389/fnut.2022.1008514. eCollection 2022.

本文引用的文献

1
Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.米诺环素治疗肌萎缩侧索硬化症患者的疗效:一项III期随机试验。
Lancet Neurol. 2007 Dec;6(12):1045-53. doi: 10.1016/S1474-4422(07)70270-3. Epub 2007 Nov 5.
2
Stromelysin-1 (MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke in mice.基质金属蛋白酶-1(MMP-3)对小鼠中风接受组织型纤溶酶原激活剂(t-PA)治疗后的颅内出血至关重要。
J Thromb Haemost. 2007 Aug;5(8):1732-9. doi: 10.1111/j.1538-7836.2007.02628.x. Epub 2007 May 21.
3
Transient neuroprotection by minocycline following traumatic brain injury is associated with attenuated microglial activation but no changes in cell apoptosis or neutrophil infiltration.创伤性脑损伤后米诺环素的短暂神经保护作用与小胶质细胞激活减弱有关,但细胞凋亡或中性粒细胞浸润无变化。
Exp Neurol. 2007 Mar;204(1):220-33. doi: 10.1016/j.expneurol.2006.10.013. Epub 2006 Dec 22.
4
Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat.在大鼠局灶性缺血中,合成基质金属蛋白酶抑制剂可逆转基质金属蛋白酶介导的脑血管紧密连接蛋白的破坏。
J Cereb Blood Flow Metab. 2007 Apr;27(4):697-709. doi: 10.1038/sj.jcbfm.9600375. Epub 2006 Jul 19.
5
Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke.延迟给予米诺环素可抑制实验性中风后缺血激活的基质金属蛋白酶2和9。
BMC Neurosci. 2006 Jul 17;7:56. doi: 10.1186/1471-2202-7-56.
6
Role of matrix metalloproteinases in delayed cortical responses after stroke.基质金属蛋白酶在中风后延迟性皮质反应中的作用。
Nat Med. 2006 Apr;12(4):441-5. doi: 10.1038/nm1387. Epub 2006 Mar 26.
7
A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease.一项关于肌酸和米诺环素治疗早期帕金森病的随机、双盲、无效性临床试验。
Neurology. 2006 Mar 14;66(5):664-71. doi: 10.1212/01.wnl.0000201252.57661.e1. Epub 2006 Feb 15.
8
Dose-response effect of tetracyclines on cerebral matrix metalloproteinase-9 after vascular endothelial growth factor hyperstimulation.四环素对血管内皮生长因子过度刺激后大脑基质金属蛋白酶-9的剂量反应效应。
J Cereb Blood Flow Metab. 2006 Sep;26(9):1157-64. doi: 10.1038/sj.jcbfm.9600268. Epub 2006 Jan 4.
9
A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia.基质金属蛋白酶-9的一种高度特异性抑制剂可在短暂性局灶性脑缺血中使层粘连蛋白免受蛋白水解,并使神经元免受凋亡。
J Neurosci. 2005 Jul 6;25(27):6401-8. doi: 10.1523/JNEUROSCI.1563-05.2005.
10
Minocycline inhibits oxidative stress and decreases in vitro and in vivo ischemic neuronal damage.米诺环素可抑制氧化应激,并减少体外和体内的缺血性神经元损伤。
Brain Res. 2005 May 17;1044(1):8-15. doi: 10.1016/j.brainres.2005.02.062. Epub 2005 Apr 13.

米诺环素在实验性卒中中延长溶栓时间窗

Extension of the thrombolytic time window with minocycline in experimental stroke.

作者信息

Murata Yoshihiro, Rosell Anna, Scannevin Robert H, Rhodes Kenneth J, Wang Xiaoying, Lo Eng H

机构信息

Neuroprotection Res Lab, Charlestown, MA 02129, USA.

出版信息

Stroke. 2008 Dec;39(12):3372-7. doi: 10.1161/STROKEAHA.108.514026. Epub 2008 Oct 16.

DOI:10.1161/STROKEAHA.108.514026
PMID:18927459
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3705574/
Abstract

BACKGROUND AND PURPOSE

Thrombolysis with tPA is the only FDA-approved therapy for acute ischemic stroke. But its widespread application remains limited by narrow treatment time windows and the related risks of cerebral hemorrhage. In this study, we ask whether minocycline can prevent tPA-associated cerebral hemorrhage and extend the reperfusion window in an experimental stroke model in rats.

METHODS

Spontaneously hypertensive rats were subjected to embolic focal ischemia using homologous clots and treated with: saline at 1 hour; early tPA at 1 hour, delayed tPA at 6 hours; minocycline at 4 hours; combined minocycline at 4 hours plus tPA at 6 hours. Infarct volumes and hemorrhagic transformation were quantified at 24 hours. Gelatin zymography was used to measure blood levels of circulating matrix metalloproteinase-9 (MMP-9).

RESULTS

Early 1-hour thrombolysis restored perfusion and reduced infarction. Late 6-hour tPA did not decrease infarction but instead worsened hemorrhagic conversion. Combining minocycline with delayed 6-hour tPA decreased plasma MMP-9 levels, reduced infarction, and ameliorated brain hemorrhage. Blood levels of MMP-9 were also significantly correlated with volumes of infarction and hemorrhage.

CONCLUSIONS

Combination therapy with minocycline may extend tPA treatment time windows in ischemic stroke.

摘要

背景与目的

组织型纤溶酶原激活剂(tPA)溶栓是美国食品药品监督管理局(FDA)批准的唯一用于急性缺血性卒中的治疗方法。但其广泛应用仍受狭窄治疗时间窗及脑出血相关风险的限制。在本研究中,我们探究米诺环素是否能预防tPA相关脑出血,并在大鼠实验性卒中模型中延长再灌注时间窗。

方法

对自发性高血压大鼠使用同源血凝块进行栓塞性局灶性缺血,并给予以下处理:1小时时给予生理盐水;1小时时给予早期tPA,6小时时给予延迟tPA;4小时时给予米诺环素;4小时时给予米诺环素联合6小时时给予tPA。在24小时时对梗死体积和出血转化进行定量分析。采用明胶酶谱法测量循环基质金属蛋白酶-9(MMP-9)的血药浓度。

结果

早期1小时溶栓可恢复灌注并减少梗死。晚期6小时tPA并未减少梗死,反而加重了出血转化。米诺环素与延迟6小时tPA联合使用可降低血浆MMP-9水平,减少梗死,并改善脑出血情况。MMP-9的血药浓度也与梗死体积和出血量显著相关。

结论

米诺环素联合治疗可能会延长缺血性卒中的tPA治疗时间窗。